Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy

Authors El Sabaa RM, Hamdi E, Hamdy NA, Sarhan HA

Received 30 March 2020

Accepted for publication 30 June 2020

Published 11 August 2020 Volume 2020:16 Pages 1945—1953

DOI https://doi.org/10.2147/NDT.S256117

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Ramy M El Sabaa,1 Emad Hamdi,2,3 Nermin Aly Hamdy,4 Hatem A Sarhan5

1Clinical Pharmacy Department, Faculty of Pharmacy, Deraya University, Minia, Egypt; 2Deraya University President, Minia, Egypt; 3Psychiatry Department, Faculty of Medicine, Cairo University, Cairo, Egypt; 4Neurology Department, Faculty of Medicine, Minia University, Minia, Egypt; 5Pharmaceutics Department, Faculty of Pharmacy, Minia University, Minia, Egypt

Correspondence: Ramy M El Sabaa
Clinical Pharmacy Department, Faculty of Pharmacy, Deraya University, Minia, New Minia 61768, Egypt
Tel +20-10-0635-0788
Email dr.ramypharma@gmail.com

Objective: This study compared the effect of levetiracetam (LEV) as monotherapy to sodium valproate (VPA) as monotherapy on cognitive functions in patients with epilepsy.
Methods: This was a comparative prospective study on 50 patients with newly diagnosed epilepsy started on antiseizure medications. Patients were selected from the neurology-outpatient clinics at Minia University Hospital, Minia, Egypt. They were divided into two groups: group treated with LEV and group treated with VPA. All patients were subjected to cognitive function assessment using reaction-time tests, trail-making tests, and Wisconsin card-sorting test before treatment and 3 months after treatment.
Results: Both groups of patients showed reduction in seizure frequency. However, patients on LEV showed significant improvement in measured cognitive functions 3 months after starting treatment, while patients in the VPA group showed significant impairment in measured cognitive functions 3 months after starting treatment.
Conclusion: Both groups of patients showed reduction in seizure frequency. However, patients on LEV showed significant improvement in measured cognitive functions 3 months after starting treatment, while patients in the VPA group showed significant impairment in measured cognitive functions 3 months after starting treatment.

Keywords: cognitive function, epilepsy, levetiracetam, valproate, monotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]